Recent years have witnessed rapid advances in the toxicologic assessment of biotechproducts.Safety assessment of a biotech product is a complex and multiple process.This includes a knowledge of its pharmaco-biological...Recent years have witnessed rapid advances in the toxicologic assessment of biotechproducts.Safety assessment of a biotech product is a complex and multiple process.This includes a knowledge of its pharmaco-biological characteristics,and identifyingthe target patient population and the proposed clinical application. To make a decision on the safe human application(the products are administering tohumans for therapeutic purposes),besides the identity and purity of the final product,展开更多
This research was aim to develop novel cyclodextrin/chitosan （CD/CS） nanocarriers for insoluble drug delivery through the mild ionic gelation method previously developed by our lab. A series of different β- cyclode...This research was aim to develop novel cyclodextrin/chitosan （CD/CS） nanocarriers for insoluble drug delivery through the mild ionic gelation method previously developed by our lab. A series of different β- cyclodextrin （β-CD） derivatives were incorporated into CS nanoparticles including hydroxypropyl-β- cyclodextrin （HP-β-CD）, sulphobutylether-β-cyclodextrin （SB-β-CD）, and 2,6-di-O-methy-βcyclodex- trin （DM-β-CD）. Various process parameters for nanoparticle preparation and their effects on physicochemical properties of CD/CS nanoparticles were investigated, such as the type of CD derivatives, CD and CS concentrations, the mass ratio of CS to TPP （CS/TRP）, and pH values. In the optimal condition, CDICS nanoparticles were obtained in the size range of 215-276 nm and with the zeta potential from 30.22 mV to 35.79 mY. Moreover, the stability study showed that the incorporation of CD rendered the CD/CS nanocarriers more stable than CS nanoparticles in PBS buffer at pH 6.8. For their easy preparation and adjustable parameters in nanoparticle formation as well as the diversified hydrophobic core of CD derivatives, the novel CD/CS nanoparticles developed herein might represent an interesting and versatile drug delivery platform for a variety of poorly water-soluble drugs with different physicochemical properties.展开更多
文摘Recent years have witnessed rapid advances in the toxicologic assessment of biotechproducts.Safety assessment of a biotech product is a complex and multiple process.This includes a knowledge of its pharmaco-biological characteristics,and identifyingthe target patient population and the proposed clinical application. To make a decision on the safe human application(the products are administering tohumans for therapeutic purposes),besides the identity and purity of the final product,
基金financially supported by Postdoctoral Science Foundation of China (No. 2014M550222)Shanghai Postdoctoral Sustentation Fund (No. 14R21410500)+2 种基金the support from School of Pharmacy, Fudan University & the Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education (No. SDD2014-2)State Key Laboratory of Molecular Engineering of Polymers (Fudan University, No. K2015-15)the Fundamental Research Funds for the Central Universities (Nos. 22A201514055 and WY1213013 ECUST)
文摘This research was aim to develop novel cyclodextrin/chitosan （CD/CS） nanocarriers for insoluble drug delivery through the mild ionic gelation method previously developed by our lab. A series of different β- cyclodextrin （β-CD） derivatives were incorporated into CS nanoparticles including hydroxypropyl-β- cyclodextrin （HP-β-CD）, sulphobutylether-β-cyclodextrin （SB-β-CD）, and 2,6-di-O-methy-βcyclodex- trin （DM-β-CD）. Various process parameters for nanoparticle preparation and their effects on physicochemical properties of CD/CS nanoparticles were investigated, such as the type of CD derivatives, CD and CS concentrations, the mass ratio of CS to TPP （CS/TRP）, and pH values. In the optimal condition, CDICS nanoparticles were obtained in the size range of 215-276 nm and with the zeta potential from 30.22 mV to 35.79 mY. Moreover, the stability study showed that the incorporation of CD rendered the CD/CS nanocarriers more stable than CS nanoparticles in PBS buffer at pH 6.8. For their easy preparation and adjustable parameters in nanoparticle formation as well as the diversified hydrophobic core of CD derivatives, the novel CD/CS nanoparticles developed herein might represent an interesting and versatile drug delivery platform for a variety of poorly water-soluble drugs with different physicochemical properties.
